Genmab AS

Genmab AS Dividend Growth

Year-over-Year Dividend Growth of Genmab AS (GMAB) as of Nov 22, 2026.

Dividend Growth

-

Last updated:

Year-over-Year Dividend Growth of Genmab AS is 2026 - . Year-over-Year Dividend Growth of Genmab AS was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genmab AS Stock analysis

What does Genmab AS do? Genmab AS is a biotechnology company based in Copenhagen, Denmark, operating in the Health Care sector. It develops and markets antibody-based therapies for cancer and other diseases, including EPKINLY, TEPKINLY, and Tivdak for various lymphomas and cervical cancer. The company also advances several product candidates in clinical development, such as Epcoritamab for lymphomas and GEN1059 for solid tumors, alongside established treatments like DARZALEX and TECVAYLI for multiple myeloma and other conditions. Genmab AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab AS stock

On Eulerpool you can find the complete historical development of Year-over-Year Dividend Growth Genmab AS since 2006 – with annual values, charts, and detailed analysis.

Dividend growth measures the percentage increase in dividends compared to the previous year. Consistent dividend growth signals financial strength and shareholder commitment.

To evaluate Year-over-Year Dividend Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Dividend Growth.

Year-over-Year Dividend Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Dividend Growth's Genmab AS historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Genmab AS

All Key Metrics — Genmab AS